Immune Reprogramming via PD-1 Inhibition Enhances Early-Stage Lung Cancer Survival

JCI insight - United States
doi 10.1172/jci.insight.96836
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Society for Clinical Investigation

Related search

Social Factors, Treatment, and Survival in Early-Stage Non-Small Cell Lung Cancer.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1998English

Aspirin‐targeted PD‐L1 in Lung Cancer Growth Inhibition

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

Is Immune Checkpoint Inhibition Part of Standard Therapy for Stage III Non-Small Cell Lung Cancer?

Cancer
Cancer ResearchOncology
2018English

Nuclear EGFR Protein Expression Predicts Poor Survival in Early Stage Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2013English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

SBRT Effective for Inoperable Early-Stage Lung Cancer

Cancer Discovery
Oncology
2014English

Correction: Quantification of CYFRA 21-1 and a CYFRA 21-1–anti-Cyfra 21-1 Autoantibody Immune Complex for Detection of Early Stage Lung Cancer

Chemical Communications
SurfacesAlloysMaterials ChemistryCoatingsMetalsOpticalMagnetic MaterialsFilmsCatalysisChemistryElectronicCompositesCeramics
2019English

P3.16-42 Early Stage Non-Small Cell Lung Cancer Survival in a Chilean Private Teaching Hospital

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-Pd-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment

Journal of Cancer
Oncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy